As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession. Seeking a Series C Salt Lake City-based Halia Therapeutics is working to close a $50 million Series C round to drive its lead asset, an NLRP3 inflammasome […]

On Dec. 1, 2022, a panel consisting of chief financial officers (CFOs) and other financial experts convened for a virtual roundtable to discuss the recent economic developments in the life sciences industry and how companies are adapting. The biopharmaceutical sector has not been immune to global economic challenges. After the COVID-19 pandemic generated a wave […]

Finding long-term, non-addictive solutions to manage chronic pain in the U.S. has long been a challenge for biopharma. In the fallout from the opioid pandemic, physicians and researchers are scrambling for options. Tuesday, a panel of experts took on stiff questions about pain/addiction therapeutics during a panel hosted by the Biotechnology Innovation Organizaion (BIO) in […]